CN104000830B - Compound crotamiton preparation and application thereof - Google Patents
Compound crotamiton preparation and application thereof Download PDFInfo
- Publication number
- CN104000830B CN104000830B CN201410211239.3A CN201410211239A CN104000830B CN 104000830 B CN104000830 B CN 104000830B CN 201410211239 A CN201410211239 A CN 201410211239A CN 104000830 B CN104000830 B CN 104000830B
- Authority
- CN
- China
- Prior art keywords
- crotamiton
- preparation
- compound recipe
- ointment
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention belongs to the technical field of medicine technology and provides a compound crotamiton preparation. Active components of the preparation comprise crotamiton and mometasone furoate. The compound crotamiton preparation is suitable for treating scabies, is high in curative effect, is good in safety, has a two-week effective rate reaching 68.33% and a four-week effective rate reaching 83.33% and is free of any obvious adverse reactions.
Description
Technical field
The invention belongs to pharmaceutical technology field and in particular to a kind of compound recipe crotamiton preparation and its preparation treatment scabies
Application in medicine.
Background technology
Scabies (scabies) is commonly called as " chancre ", is to be colonized in a kind of contact causing in human body skin top layer to pass by sarcoptic mite
Metachromia dermatosiss.Sarcoptic mite belongs to demodicid mite and belongs to, and also known as acaricide, is a kind of permanent parasitic mite.Colonize in the skin of people and mammal
Interior, invade human body, that is, cause scabies.Acaricide multiparasitization, at the relatively thin position of skin, is webs and its both sides, the fossa cubitalis, axillary fossa, female
At fold under property breast, umbilicuss week, groin, penis, scrotum etc..Because acaricide is in the machinery thorn of keratodermatitis tunneling
Swash and the toxinferous stimulation of acaricide, the inflammation of skin and violent prurituss can be caused.Infringement is from the beginning of for pinhead-sized pimple, mound
Herpess or phlysis.Chang Yin scratches and causes scratch, blood crustss, pigmentation, the change of eczema sample or secondary infection pustule, furuncle and phyma,
Minority can occur nephritis and exfoliative dermatitiss.Often scabies tuberosity can be formed at penis, scrotum, such as treat not in time, the state of an illness can be by
Gradually increase, delay the several months, infect other people simultaneously.Can flow in the poor rural area of sanitary condition, cities and towns and building site crowd in China
OK.
The treatment of current scabies only has the preparations such as sulfur frost preparation, benzyl benzoate cream, crotamiton emulsifiable paste.Sulfur
The preparations such as frost, benzyl benzoate cream are big due to stink, have certain zest, some patient's coming in contact property dermatitis etc. are bad
Reaction is it is impossible to be accepted by patients.
Crotamiton emulsifiable paste (trade name Eurax), for treating scabies prurituss.The advantage of crotamiton emulsifiable paste is that do not have
Scent of, but in its product description, the untoward reaction listed is " can cause contact dermatitis allergy ", and points for attention include
" situations such as agents area is if any burn feeling, redness should be discontinued, and topical remedy is cleaned, and seeks advice to doctor if necessary.”
Urgent clinical needs one kind does not have abnormal smells from the patient at present, will not cause contact dermatitis allergy, can effectively treat in time after medication
The external preparation of scabies.
Content of the invention
It is an object of the invention to provide contact dermatitis allergy will not be caused after a kind of medication and can effectively treat in time
The compound recipe crotamiton preparation of scabies.
Another object of the present invention is to providing application in preparation treatment scabies medicine for this compound recipe crotamiton preparation.
The present inventor, in long-term department of dermatologry clinical practice, finds currently used for treatment eczema, neurodermatitiss, dystopy
Property dermatitis and skin prurituss momestasone furoate, if with crotamiton form compound preparation, crotamiton can not only be improved soft
The untoward reaction of cream, has rapid anti-inflammatory, mitigates prurituss and other effects, and the two combination has collaborative work to the treatment of scabies
With.
A first aspect of the present invention, there is provided a kind of compound recipe crotamiton preparation, the active ingredient of said preparation is Crow
In rice grain pattern and momestasone furoate, and preparation, crotamiton and the percentage by weight of momestasone furoate are 10-30 1, preferably 20
1.
The compound recipe crotamiton preparation of the present invention is external preparation, such as ointment, ointment, gel, paste etc..
The compound recipe crotamiton preparation of the present invention, can be using this when preparing ointment, ointment, gel, paste etc.
Pharmaceutic adjuvant known to field.
Preferably, present invention also offers a kind of compound recipe crotamiton ointment, the content of crotamiton in this ointment
For 10%, the content of momestasone furoate is 0.5%, by weight.
Further, in this ointment, the percentage by weight of each component is as follows:
The ointment of the preparation present invention, can be using lapping-in method well known in the art, fusion process and emulsion process etc..
A second aspect of the present invention, there is provided above-mentioned compound recipe crotamiton preparation in preparation treatment scabies medicine
Application.
In the formula of the present invention, wherein crotamiton is anti-itch mite medicine, acts on the nervous system of sarcoptic mite, so that sarcoptic mite is benumbed
And it is dead；In addition still have slight local anesthetic action and can be antipruritic.
In the formula of the present invention, wherein momestasone furoate has quickening inflammatory resolution, antipruritic, prevents crotamiton from causing
Contact dermatitis etc. act on, and momestasone furoate is " soft hormone " simultaneously, on the one hand has high partial result, on the other hand exists
Local is inactive catabolite by cruel enzyme rapid metabolization, thus decrease the suppression to hypothalmus-pituitary-adrenal axis and
Local untoward reaction, therefore it is particularly well-suited to child skin.
The compound recipe crotamiton that the present invention provides is it is adaptable to scabies.This product curative effect is high, and safety is good, its two weeks effective percentage
Reach 68.33%, surrounding effective percentage reaches 83.33%.With respect to crotamiton emulsifiable paste, this product has inflammatory resolution soon, antipruritic effect
Good, effectively prevent the contact dermatitis of crotamiton initiation simultaneously.
The compound recipe crotamiton preparation of the present invention, has curative effect height, antipruritic fast, no obvious adverse reaction, and cost is relatively
Low, easily it is accepted by patients, such as promotes the use of, obvious economic benefit and social benefit can be produced.
Specific embodiment
With reference to embodiment, the present invention is described in further detail, but the enforcement of the present invention is not limited only to this.
Embodiment 1: the preparation of compound recipe crotamiton ointment
The composition of every 1000g ointment is as follows:
Take glyceryl monostearate, stearic acid heating and melting, temperature is maintained at 70～80 DEG C, separately takes crotamiton, furancarboxylic acid
Mometasone, glycerol and appropriate amount of water, grind to form suspension, are slowly added in oil phase, stir to same direction and obtain final product to cooling.
Embodiment 2: the test of pesticide effectiveness of compound recipe crotamiton ointment of the present invention
First, data and method
1st, case: select the scabies patient 120 that Shanghai Long March Hospital's Dermatology Outpatient Department is clarified a diagnosis for 2010 to 2014 years
As object of study, the course of disease 1 to 2 week.Inclusion criteria: have contagion history, the morbidity of common colony；There is mound at the thin tender position of skin
The erythra such as rash, papulovesicle, tuberosity, tunnel；Sarcoptic mite can be found at infringement.Rejecting standard: Pregnant and lactant women；To chromium
Lead to or momestasone furoate allergy sufferers；It is presently using additive method treatment scabies person.
2nd, it is divided into two groups according to table of random number.Treatment group: 60, male 42, women 18, the age 18～34
Year, average 23.5 years old.Matched group: 60, male 41, women 19,17～32 years old age, average 22.9 years old.
3rd, Therapeutic Method: treatment group: applied using the preparation of the present invention and put whole skin beyond Head And Face on the skin, apply second after 24h
Secondary, then have a bath after being spaced 48h medicine is washed away, wear clean clothes, more change the sheet quilt cover, be repeated 1 times after 1 week.Matched group external
Crotamiton, the same treatment group of usage.2 weeks, evaluate curative effect respectively after 4 weeks.(coating about 30g ointment, comprises in treatment group every time
About 3g crotamiton, 0.15g momestasone furoate, matched group comprises about 3g crotamiton)
4th, efficacy determination: by level Four standard.Recovery from illness: whole body no prurituss, original deflorescence, no new breakout, Nan Xingyin
Capsule tuberosity diminishes or no new tuberosity occurs；Effective: prurituss that whole body is slight, there is erythema to grab crust, no newly send out pimple, papulovesicle, knot
Section；Invalid: whole body prurituss do not mitigate, there is new breakout.
5th, result: two groups of sexes, age differencess are not statistically significant.Treatment group and treatment of control group the results are shown in Table 1, recovery from illness
Plus effective for effective percentage, total effective rate when two groups two weeks is respectively 68.33% and 38.33%, and total effective rate during surrounding divides
Not Wei 83.33% and 60.00%, be statistically analyzed that all there were significant differences (p 0.01), illustrate treatment group's curative effect apparently higher than
Matched group.
Table 1 treatment group and matched group comparitive study
It can be seen that, two weeks effective percentage of compound recipe crotamiton that the present invention provides reach 68.33%, and surrounding effective percentage reaches 83.33%,
Crotamiton emulsifiable paste far above folk prescription.And this product has inflammatory resolution soon, antipruritic effect is good, uses merely crotamiton, office
Portion's prurituss inflammation substantially, plus with after hormone, in 8 hours, prurituss go down, and effectively prevent the contact of crotamiton initiation simultaneously
Property dermatitis.
Below the preferred embodiment to the invention is illustrated, but the invention be not limited to described
Embodiment, those of ordinary skill in the art also can make without prejudice on the premise of the invention spirit a variety of equivalent
Modification or replacement, these equivalent modifications or replacement are all contained in the application claim limited range.
Claims (6)
1. a kind of compound recipe crotamiton preparation it is characterised in that said preparation active ingredient be crotamiton and momestasone furoate,
And crotamiton and the percentage by weight of momestasone furoate are 20 1 in preparation.
2. a kind of compound recipe crotamiton preparation according to claim 1 is it is characterised in that described compound recipe crotamiton system
Agent is ointment, gel or paste.
3. a kind of compound recipe crotamiton preparation according to claim 1 is it is characterised in that described compound recipe crotamiton system
Agent is ointment.
4. a kind of compound recipe crotamiton preparation according to claim 1 is it is characterised in that described compound recipe crotamiton system
Agent is ointment, and in ointment, the content of crotamiton is 10%, and the content of momestasone furoate is 0.5%, by weight.
5. a kind of compound recipe crotamiton preparation according to claim 4 it is characterised in that in this ointment each component weight
Amount percentage ratio is as follows:
6. the answering in preparation treatment scabies medicine of the compound recipe crotamiton preparation as described in a kind of any one as claim 1 to 5
With.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410211239.3A CN104000830B (en) | 2014-05-19 | 2014-05-19 | Compound crotamiton preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410211239.3A CN104000830B (en) | 2014-05-19 | 2014-05-19 | Compound crotamiton preparation and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104000830A CN104000830A (en) | 2014-08-27 |
| CN104000830B true CN104000830B (en) | 2017-02-01 |
Family
ID=51361920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410211239.3A Active CN104000830B (en) | 2014-05-19 | 2014-05-19 | Compound crotamiton preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104000830B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104906173A (en) * | 2015-06-25 | 2015-09-16 | 浙江理工大学 | Antibacterial itching relieving preparation and preparation method thereof |
| CN107115329A (en) * | 2017-04-28 | 2017-09-01 | 中国人民解放军第二军医大学第二附属医院 | A kind of compound Butenafine preparation and its application |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7887842B2 (en) * | 2003-02-07 | 2011-02-15 | Teikoku Pharma Usa, Inc. | Methods of administering a dermatological agent to a subject |
-
2014
- 2014-05-19 CN CN201410211239.3A patent/CN104000830B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104000830A (en) | 2014-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Takahashi et al. | High-dose intravenous vitamin C improves quality of life in cancer patients | |
| JP6159084B2 (en) | Composition containing berberine or an analogue thereof for treating skin diseases associated with rosacea or blush | |
| KR102587297B1 (en) | A composition for preventing or treating sleep disturbance | |
| Kloner et al. | Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension | |
| CN105193672A (en) | Cell regeneration and restoration essence and preparation method thereof | |
| CN103285155A (en) | Traditional Chinese medicine composition for treating eczema and dermatitis | |
| CN104000830B (en) | Compound crotamiton preparation and application thereof | |
| Maghrabi et al. | Norwegian crusted scabies: an unusual case presentation | |
| CN104173871A (en) | Traditional Chinese medicine composition for treating vulvitis and applications of traditional Chinese medicine composition | |
| CN102614194B (en) | Externally applied medicine for treating skin disease and application thereof | |
| CN104771405A (en) | Compound terbinafine preparation and applications thereof | |
| El-Darouti et al. | Hypopigmented parapsoriasis en plaque, a new, overlooked member of the parapsoriasis family: a report of 34 patients and a 7-year experience | |
| CN107441071B (en) | A kind of application of ar-turmerone in preparation treatment and/or prevention psoriasis | |
| Lone et al. | Clinical efficacy and safety of a pharmacopial polyherbal Unani formulation in pityriasis versicolor: A comparative randomized single-blind study | |
| US7731993B2 (en) | Composition for treating a dermal anomaly | |
| Khamaganova | Alleviation of a severe pruritic flare‐up in a 13‐year‐old child with chronic atopic dermatitis treated with methylprednisolone aceponate 0.1% | |
| CN111407770A (en) | Composition for treating skin diseases and application thereof | |
| CN102600177B (en) | External medicament for treating skin diseases and application thereof | |
| CN102631406A (en) | Mouthwash for oral ulcer | |
| CN103040942B (en) | Traditional Chinese medicine composition for treating psoriasis | |
| Lehmberg et al. | Skin plaques mimicking psoriasis | |
| CN108969531A (en) | Polyethylene glycol is preparing application and its drug in curing psoriasis drug as active constituent | |
| CN101337006B (en) | Compound liniment for treating acne | |
| CN102138934B (en) | Emulsifiable paste for treating scabies | |
| Berger et al. | Skin disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |